Prosecution Insights
Last updated: November 04, 2026
Application No. 18/307,200

Fully Printed Electrode Biological Interface

Final Rejection §103§112
Filed
Apr 26, 2023
Priority
Apr 27, 2022 — provisional 63/335,499
Examiner
TURK, NEIL N
Art Unit
1798
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Early Charm Ventures
OA Round
2 (Final)
51%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
395 granted / 774 resolved
-14.0% vs TC avg
Strong +44% interview lift
Without
With
+44.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
40 currently pending
Career history
821
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
34.1%
-5.9% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
39.0%
-1.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 774 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action fully acknowledges Applicant’s remarks filed on February 16th, 2016. Claims 1-21 are pending. Claims 1-14, 19, and 20 are withdrawn from consideration. Claim 21 is newly added. Claims 15-18, and 21 are under examination. Request for Information under 37 CFR 1.105 No IDS was filed for this application. The applicant and/or the assignee of this application are required under 37 CFR 1.105 to provide the following information that the examiner has determined is reasonably necessary to the examination of this application (see MPEP §§ 704.10 - 704.13). In response to this requirement, please provide a copy of any related and pertinent information, such as non-patent literature, published application(s) or patent(s) (U.S. or foreign), that was used to assist in the drafting of this application. The applicant is reminded of the duty to disclose information that is material to patentability (see 37 CFR § 1.56). A complete reply to the instant Office action must include a complete reply to this requirement. The time period for reply to this requirement coincides with the time period for reply to the instant Office action. *Examiner notes that Applicant has supplied the three cited pieces of non-patent literature, however, a formal IDS form submission has not been made introducing these publications. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The metes and bounds of the sought first/second/third composite layers are indefinitely provided herein. The term “composite” connotes being made up of multiple parts or elements, however, the individual first/second/third composite layers are recited as comprising a single element in that of 1) biocompatible hydrogel, 2)tissue layer, 3)conductive layer. By this, does Applicant intend that collectively the first/second/third layers provide a “composite” layer given their different elements and the term “composite” applied to the individual layers is nothing more than a nominal qualifier to each layer? If Applicant does not intend this then Applicant is invited to clarify the first/second/third layers and their composite nature by way of an additional element to each of the first/second/third layers. It is further noted that Applicant’s specification discloses first/second/third composites comprising first/second/third compositions, wherein par.[0005] sets forth these compositions- Layer 1) selected from one of a conductive ink, biocompatible hydrogel, live cell loaded biocompatible hydrogel, or live cells. Layer 2) selected from one of a conductive ink biocompatible hydrogel, live cell loaded biocompatible hydrogel, or live cells. Layer 3) selected from one of a conductive ink biocompatible hydrogel, live cell loaded biocompatible hydrogel, or live cells. The disclosure also provides the non-limiting discussion that the first/second/third compositions may be the same or different (and as seen above, comprise selecting one of from a equivalent listing in all three). Par.[0024] speaks to live cell layers of different composition that is not relevant herein to the defined first/second/layers. Par.[0033] speaks to likewise discussion as in par.[0005] and that the applied layers can be the same or different, but as above, this does not speak to a composite nature of the individual layers themselves. If the individual layers themselves are meant as composites, clarification is required as to their additional element(s) provided given that the present recitation affords a singular element to each. If the layers themselves collectively provide a composite stack by way of the different elements to each of the first/second/third layers than the claim recitations to the individual layers should avoid the term “composite.” Clarification is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 15, 17, 18, and 21, as best understood, are rejected under 35 U.S.C. 103 as being unpatentable over Guvendiren et al. (USPN 11,806,444), hereafter Guvendiren, in view of Richardson-Burns et al. (US 2011/0087315), hereafter Richardson. With regard to claim 15, Guvendiren discloses a multilayer biologic apparatus for toxicity screening in live cells comprising a support matrix comprising a sterilizable material (base supporting polymer layer; lines 25-31, col. 4, abstract, for example), a first composite layer comprising a biocompatible hydrogel layer wherein the first composite layer is deposited on the support matrix (“first functional hydrogel gel layer”; lines 25-31, col. 4, for example), a second composite layer comprising a tissue layer that overlays the first composite layer (see “second functional layer” and constituted as comprising a biocompatible hydrogel printed/impregnated with live cells as in claim 17; lines 40-42, col. 2; lines 40-55, col. 5, for example). With regard to claim 15, Guvendiren does not specifically disclose a third composite layer comprising a conductive layer to monitor toxicology response wherein the third composite layer overlays the second composite layer. With regard to claim 18, Guvendiren does not specifically disclose the biocompatible hydrogel is one of those as listed with a gel melt(set) temperature of greater tan about 40 degrees Celsius. With regard to claim 21, Guvendiren does not specifically disclose the conductive layer is a printed electrode as claimed. Richardson discloses co-electrodeposited hydrogel-conducting polymer electrodes for biomedical applications (abstract). Richardson discloses a hydrogel seeded with biological components including living cells, and discloses a conductive layer to monitor toxicology comprising a printed electrode around the tissue/living cells (lines 25-44, col. 8; lines 25-67, col. 16; lines 11-35, col. 20). Richardson further discloses that alternative hydrogels to be used include PEG or gelatin, for example (lines 59-64, col. 20, for example). It would have been obvious to one of ordinary skill in the art to modify Guvendiren to provide a conductive layer, as a printed electrode, overlaying the tissue layer such as suggested by the analogous art of Richardson to hydrogel-conducting polymer electrodes for biomedical applications in which Guvendiren provides a biomedical application in a biocompatible 3D cell construct in which the added conductive, printed electrode layer to the cells provides the benefit of sensing functionality to monitor biological processes of the cells. Further, to the extent that Richardson provides a conductive layer that is position around the living cells and does not overlay the living cells, such a modification would have been obvious to one of ordinary skill in the art through routine engineering design to provide an alternative disposition that remains to afford the desired contact and electrical conductive/sensing capabilities with the live cells that would have a reasonable expectation of success therein. This is maintained as an obvious engineering design modification for the reasons discussed above and absent a showing of a criticality or unexpected results arising otherwise. Further, it would have been obvious to one of ordinary skill in the art to modify Guvendiren to utilize a hydrogel selected from the group as recited in claim 18 such as suggested by the analogous subject matter of Richardson in order to provide an obvious alternative hydrogel material and one in which affords the conductive pathway for the desired electrical sensing functionalities. Further, while not explicitly disclosed in Richardson, given that Richardson provides for physiological applications of the device for biomedical applications, it would be apparent to one of ordinary skill in the art to choose a PEG or gelatin hydrogel that has a gel melt temperature greater than about 40 degrees Celsius so as to provide a hydrogel that maintains its stable state during physiological biomedical applications wherein an expected operating temperature can range from 37 (about 98.6F) to greater than about 40 degrees Celsius for covering the range of internal body temperature depending on the user’s state (i.e. inflammatory/fever or non-inflammatory) and would be appreciated by Guvendiren/Richardson in providing a workable, physiological cell evaluation biomedical, physiological device to expected conditions. See also MPEP 2144, II, A. Claim(s) 16 is/are rejected under 35 U.S.C. 103 as being unpatentable over Guvendiren in view of Richardson as applied to claims 15, 17, 18, and 21 above, and further in view of Hatch (USPN 10,988,723). Guvendiren/Richardson does not specifically disclose the sterilizable material of the support matrix is one of those listed as in claim 16. Hatch discloses modular assemblies and systems for cell cultures (abstract). Hatch discloses that the support material for the biological membrane may comprise a polyester or a polycarbonate (lines 55-58, col. 16; lines 20-35, col. 33, for example). It would have been obvious to one of ordinary skill in the art to modify Guvendiren/Richardson to utilize a support matrix comprising a sterilizable material as in polyester or polycarbonate such as taught by the analogous art of Hatch to a cell culture assembly in which a support matrix comprising polyester or polycarbonate provides an obvious alternative choosing of material for a porous support to a biological membrane that affords diffusion of nutrients, oxygen, metabolites, etc…and a robust structure for handling and reinforcement of the cell construct in Guvendiren/Richardson. Response to Arguments Applicant’s arguments with respect to claim(s) 15-18 and 21 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. See the body of the action above in which new grounds of rejection have been provided over the claims in view of the amendments made herein. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL N TURK whose telephone number is (571)272-8914. The examiner can normally be reached M-F 930-630. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Capozzi can be reached at 571-270-3638. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NEIL N TURK/Primary Examiner, Art Unit 1798
Read full office action

Prosecution Timeline

Apr 26, 2023
Application Filed
Nov 18, 2025
Non-Final Rejection mailed — §103, §112
Feb 16, 2026
Response Filed
Oct 05, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782347
Bionanomechanical Devices for Uses in Evaluating Liquid Dynamics
4y 2m to grant Granted Nov 03, 2026
Patent 12782284
NON-LINEAR SINGLE-MOLECULE FRET AND POLARIZATION-SWEEP SINGLE-MOLECULE MICROSCOPY
4y 1m to grant Granted Nov 03, 2026
Patent 12779468
TARGET PARTICLE EJECTION FROM RECIRCULATING FLUID EJECTION CHANNELS
3y 10m to grant Granted Nov 03, 2026
Patent 12781179
Apparatus for Tissue Lysis Under Electromagnetic Field Control
2y 5m to grant Granted Nov 03, 2026
Patent 12748057
Nano and Microscale Patterned Surfaces for Centering a Droplet
3y 9m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
51%
Grant Probability
95%
With Interview (+44.2%)
3y 9m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 774 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month